Nautilus Biotechnology Inc (NAUT)

Currency in USD
2.730
-0.410(-13.06%)
Closed·
2.740+0.010(+0.37%)
·
Advertisement
NAUT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.6403.080
52 wk Range
0.8414.310
Key Statistics
Prev. Close
3.14
Open
2.88
Day's Range
2.64-3.08
52 wk Range
0.841-4.31
Volume
7.98M
Average Volume (3m)
5.28M
1-Year Change
93.617%
Book Value / Share
0.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAUT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.000
Upside
+46.52%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Nautilus Biotechnology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.000
(+46.52% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Roth/MKM
Buy3.50+28.21%-New Coverage29/09/2026
Leerink
Buy4.00+46.52%-New Coverage09/09/2026
Guggenheim
Buy4.00+46.52%2.50Maintain27/02/2026

Nautilus Biotechnology Inc Earnings Call Summary for Q3/2026

  • Nautilus beat Q3 estimates with $0.12 loss/share vs. $0.14 expected; revenue of $230K topped $206K forecast; shares rose 3.28% to $2.52.
  • Company raised 2026 revenue guidance above prior $0.5M target; cash of $114.3M extends runway into Q1 2028 with single-digit opex growth expected.
  • Beta Voyager platform placement targeted by end-2026; commercial launch slated early 2027 with instrument shipments mid-2027; 100x sample reduction planned.
  • Management highlighted progress on proteoform assays including tau, AKT1, EGFR, P53; oncology assays reaching performance targets faster than expected.
  • Analysts maintain Strong Buy rating with $3.50-$4.00 targets implying 57% upside; key risks include limited revenue base and pre-commercial status.
Last Updated: 27/10/2026, 13:34
Read Full Transcript

Earnings

Latest Release
27/10/2026
EPS / Forecast
-0.12 / -0.14
Revenue / Forecast
230K / 206.25K
EPS Revisions
Last 90 days

Compare NAUT to Peers and Sector

Metrics to compare
NAUT
Peers
Sector
Relationship
P/E Ratio
−6.8x−2.7x−0.3x
PEG Ratio
−0.94−0.130.00
Price/Book
3.4x1.6x2.6x
Price / LTM Sales
943.3x8.6x2.9x
Upside (Analyst Target)
46.5%13.4%62.2%
Fair Value Upside
Unlock23.3%8.6%Unlock

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
8.14M6.40%26.14M
Other Institutional Investors
69.06M54.27%221.68M
Public Companies & Retail Investors
50.05M39.33%160.68M
Total
127.26M100.00%408.49M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Perceptive Advisors LLC9.14%11,634,21137,346
Perceptive Life Sciences Master Fund, Ltd.9.01%11,468,35136,813

People Also Watch

99.180
KOD
-1.22%
138.37
VST
-1.83%
12.270
ABCL
-6.19%
8.29
IBRX
-5.15%
69.050
AAOI
-12.80%

FAQ

What Is the Nautilus Biotechnology (NASDAQ: NAUT) Share Price Today?

The Nautilus Biotechnology stock price today is 2.730 USD.

What Stock Exchange Does Nautilus Biotechnology (NAUT) Trade On?

Nautilus Biotechnology is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Nautilus Biotechnology?

The stock symbol (also called a 'ticker') for Nautilus Biotechnology is "NAUT."

What Is the Current Nautilus Biotechnology Market Capitalisation?

As of today, Nautilus Biotechnology (NASDAQ: NAUT) market cap is 399.950M USD.

What Is Nautilus Biotechnology's (NAUT) Earnings Per Share (TTM)?

The Nautilus Biotechnology EPS is currently -0.46 (Trailing Twelve Months).

When Is the Next Nautilus Biotechnology Earnings Date?

Nautilus Biotechnology's next earnings report will be released on 04/03/2027.

Is NAUT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Nautilus Biotechnology moving averages and other technical indicators, the daily buy/sell signal for NAUT stock is Strong Buy.

How Many Times Has Nautilus Biotechnology Stock Split?

Nautilus Biotechnology has split 0 times. (See the NAUT stock split history page for full effective split date and price information.)

How Many Employees Does Nautilus Biotechnology Have?

Nautilus Biotechnology has 128 employees, based on their latest Companies House report.

What is the current trading status of Nautilus Biotechnology (NASDAQ: NAUT)?

As of 30/10/2026, Nautilus Biotechnology (NAUT) is trading at a share price of 2.730 USD, with a previous close of 3.140 USD. The stock has fluctuated within a day range of 2.640 USD to 3.080 USD, while its 52-week range spans from 0.841 USD to 4.310 USD.

What Is Nautilus Biotechnology (NAUT) Price Target According to Analysts?

The average 12-month price target for Nautilus Biotechnology is 4.000 USD, with a high estimate of 4 USD and a low estimate of 4 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +46.52% Upside potential.

What Is the NAUT Premarket Price?

NAUT's last pre-market stock price is 2.920 USD. The pre-market share volume is 189,790.000, and the stock has decreased by -0.220, or -7.010%.

What Is the NAUT After Hours Price?

NAUT's last after hours stock price is 2.740 USD, the stock has decreased by 0.010, or 0.370%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.